Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Proof of Concept Study Evaluating the Safety and Tolerability of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

NCT05725057 is registered in ClinicalTrials.gov with Artax Biopharma Inc as lead sponsor.

NCT NCT05725057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05725057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Proof of Concept Study Evaluating the Safety and Tolerability of AX-158 in Patients With Mild to Moderate Plaque Psoriasis
Lead sponsor
Artax Biopharma Inc
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2023
Completion date
October 4, 2024
Enrollment
31 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriasis